Condition: Non-small Cell Lung Cancer · Sponsor: BioNTech SE
This is a Phase II, multisite, open-label study consisting of two parts in participants with advanced/metastatic Non-small Cell Lung Cancer (NSCLC) which progressed after a first-line chemoimmunotherapy to evaluate the combination of pumitamig (also known as BNT327, BMS-986545 or PM8002) with standard of care. Part 1 is a safety run-in with pumitamig (Dose 1 or Dose 2) plus docetaxel and will include up to 12 participants in total to be treated in Part 1A and 1B sequentially. Part 2 is a dose expansion at the deemed safe dose of pumitamig plus docetaxel and will include up to 54 participants.
This description comes directly from the study's public registry record.
BioNTech clinical trials patient information · +49 6131 9084 · patients@biontech.de
Always discuss trial participation with your own doctor first.
| The University of Alabama at Birmingham Hospital | Birmingham, Alabama, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Baptist Health Hardin | Elizabethtown, Kentucky, United States | Recruiting |
| NYU Langone - NYU Grossman School of Medicine | New York, New York, United States | Recruiting |
| Texas Oncology, P.A. | Houston, Texas, United States | Completed |
| Liverpool Cancer Therapy Centre | Liverpool, New South Wales, Australia | Recruiting |
| Metro South Health - Princess Alexandra Hospital (PAH) | Woolloongabba, Queensland, Australia | Recruiting |
| Cancer Research SA (CRSA) | Adelaide, South Austraila, Australia | Recruiting |
| Hobart Hospital-Royal Hobart Hospital | Hobart, Tasmania, Australia | Recruiting |
| One Clinical Research - Hollywood Private Hospital | Nedlands, Western Australia, Australia | Recruiting |
| Gyeongsang National University Hospital (GNUH) | Jinju, Gyeongsangnam-do, South Korea | Recruiting |
| Chungbuk National University Hospital | Cheongju-si, South Korea | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06841055